Here are the S-1 registration statements from Apnimed, Inc. (APMD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow APMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APMD filings page.
Apnimed, Inc. plans an initial public offering of 10,000,000 shares of common stock at an expected price range of $14.00–$16.00 per share, with an underwriters’ option for up to 1,500,000 additional shares. At the $15 midpoint, it expects net proceeds of about $134.6 million, leaving 37,999,640 shares outstanding.
The company is a late-stage clinical pharmaceutical business focused on sleep-related breathing disorders. Its sole clinical candidate, Oxnimbi (AD109), showed statistically significant reductions in apnea hypopnea index and hypoxic burden in two Phase 3 OSA trials, and an NDA was accepted by the FDA with a PDUFA goal date of February 28, 2027.
Apnimed reported $84.8 million in related-party revenue and net income of $67.7 million in the quarter ended March 31, 2026, but discloses substantial doubt about its ability to continue as a going concern and expects significant future losses. Offering proceeds plus cash are earmarked primarily to fund Oxnimbi’s regulatory review and, if approved, U.S. launch.